Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

NaPi2b-targeted antibody-drug conjugate

DRUG CLASS:

NaPi2b-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

SLC34A2 expression	Ovarian Cancer	SLC34A2 expression	Ovarian Cancer	XMT-1536 Sensitive: C2 – Inclusion Criteria XMT-1536 Sensitive : C2	XMT-1536 Sensitive: C2 – Inclusion Criteria XMT-1536 Sensitive : C2
SLC34A2 expression	Non Small Cell Lung Cancer	SLC34A2 expression	Non Small Cell Lung Cancer	XMT-1536 Sensitive: C2 – Inclusion Criteria XMT-1536 Sensitive : C2	XMT-1536 Sensitive: C2 – Inclusion Criteria XMT-1536 Sensitive : C2
SLC34A2 overexpression	Ovarian Cancer	SLC34A2 overexpression	Ovarian Cancer	DNIB0600A Sensitive: C3 – Early Trials DNIB0600A Sensitive : C3	DNIB0600A Sensitive: C3 – Early Trials DNIB0600A Sensitive : C3
SLC34A2 overexpression	Non Small Cell Lung Cancer	SLC34A2 overexpression	Non Small Cell Lung Cancer	DNIB0600A Sensitive: C3 – Early Trials DNIB0600A Sensitive : C3	DNIB0600A Sensitive: C3 – Early Trials DNIB0600A Sensitive : C3
SLC34A2 overexpression	Ovarian Cancer	SLC34A2 overexpression	Ovarian Cancer	XMT-1536 Sensitive: C3 – Early Trials XMT-1536 Sensitive : C3	XMT-1536 Sensitive: C3 – Early Trials XMT-1536 Sensitive : C3
SLC34A2 expression	Non Small Cell Lung Cancer	SLC34A2 expression	Non Small Cell Lung Cancer	XMT-1592 Sensitive: D – Preclinical XMT-1592 Sensitive : D	XMT-1592 Sensitive: D – Preclinical XMT-1592 Sensitive : D
SLC34A2 expression	Ovarian Cancer	SLC34A2 expression	Ovarian Cancer	XMT-1592 Sensitive: D – Preclinical XMT-1592 Sensitive : D	XMT-1592 Sensitive: D – Preclinical XMT-1592 Sensitive : D
SLC34A2 expression	Ovarian Cancer	SLC34A2 expression	Ovarian Cancer	ZW220 Sensitive: D – Preclinical ZW220 Sensitive : D	ZW220 Sensitive: D – Preclinical ZW220 Sensitive : D